Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 3/20 | 0.48 |
| ▸ | NSD2 | O96028 | 3/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PTPRC | P08575 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.44 |
| ▸ | S100A4 | P26447 | 6/20 | 0.41 |
| ▸ | CDC25B | P30305 | 3/20 | 0.41 |
| ▸ | PADI1 | Q9ULC6 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL9604110 | 0.89 | TDP1 (0.42) | TDP2NSD2PAX8TDP1ABL1 | |
| SCHEMBL300666 | 0.87 | TDP2 (0.46) | TDP2NSD2PAX8TDP1ABL1 | |
| Benzoic Acid SCHEMBL1879517 | 0.73 | NAPRT (0.45) | TDP1CES1MEN1BLMKMT2A | |
| SCHEMBL32689420 | 0.73 | TDP1 (0.39) | TDP2NSD2PAX8TDP1ABL1 | |
| SCHEMBL32689421 | 0.71 | TDP1 (0.38) | TDP2NSD2PAX8TDP1ABL1 | |
| SCHEMBL2967094 | 0.70 | TDP2 (0.58) | TDP2NSD2PAX8TDP1ABL1 | |
| SCHEMBL31288011 | 0.70 | TDP1 (0.37) | TDP2NSD2PAX8TDP1ABL1 | |
| SCHEMBL1895059 | 0.70 | TDP1 (0.37) | TDP2NSD2PAX8TDP1ABL1 | |
| SCHEMBL10434479 | 0.69 | TDP2 (0.47) | TDP2NSD2PAX8TDP1ABL1 | |
| SCHEMBL9709207 | 0.68 | TDP2 (0.55) | TDP2NSD2PAX8TDP1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009051504-A1 | BENZO- AND PYRIDOPYRIDAZINONES WITH ANALGESIC AND ANTIINFLAMMATORY ACTIVITY | UNIWERSYTET LODSKI (PL) | 2009-04-23 | — | — | WO | claimed |
| CN-111606928-A | Azacyclodiketone compound and preparation method thereof | 维清生物科技(上海)有限公司 | 2020-09-01 | — | — | CN | disclosed |
| CN-111217810-A | Azacyclodiketone compound and preparation method thereof | 维清生物科技(上海)有限公司 | 2020-06-02 | — | — | CN | disclosed |
| EP-2251327-B1 | HETEROCYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8431574-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130018075-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-01-17 | — | — | US | disclosed |
| US-20120263679-A1 | Combinations Comprising Heterocyclic Inhibitors of MEK and Methods of Use Thereof | ARRAY BIOPHARMA INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8268852-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8211921-B2 | Heterocyclic inhibitors of MEK and methods of use | ARRAY BIOPHARMA INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211920-B2 | 6-oxo-1,6-dihydropyridine derivatives as inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20090143389-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090131435-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2009051504-A1 | BENZO- AND PYRIDOPYRIDAZINONES WITH ANALGESIC AND ANTIINFLAMMATORY ACTIVITY | UNIWERSYTET LODSKI (PL) | 2009-04-23 | — | — | WO | disclosed |
| US-7517994-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| EP-1682138-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1682138-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-10 | — | — | US | disclosed |
| WO-2005051301-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | TDP2 1679/4885NSD2 1547/4885PAX8 3899/4885 |
| US-20090131435-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE | NRAS, BRAF, MAPK9 | TDP2 1736/4885NSD2 1321/4885PAX8 3974/4885 |
| US-20090143389-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | TDP2 1826/4885NSD2 1718/4885PAX8 4267/4885 |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | TDP2 1828/4885NSD2 1993/4885PAX8 4010/4885 |
| US-20130018075-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, RAF1 | TDP2 1504/4885NSD2 1201/4885PAX8 4203/4885 |
| US-20120263679-A1 | Combinations Comprising Heterocyclic Inhibitors of MEK and Methods of Use Thereof | NRAS, BRAF, CDK9 | TDP2 1890/4885NSD2 977/4885PAX8 3566/4885 |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | TDP2 1814/4885NSD2 1864/4885PAX8 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.